SEARCH

SEARCH BY CITATION

References

  • Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry 65:135144.
  • Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, Koivisto T, Makela R, Kranzler HR (2008) Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res 32:11591166.
  • Barr CS, Chen SA, Schwandt ML, Lindell SG, Sun H, Suomi SJ, Heilig M (2010) Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor locus. Biol Psychiatry 67:7880.
  • Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276:31303137.
  • Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P, Niaura R, Lerman C (2007) Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 61:111118.
  • Beyer A, Koch T, Schroder H, Schulz S, Hollt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89:553560.
  • Bhaduri N, Mukhopadhyay K (2008) Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: a study on Eastern Indian population. Cell Mol Neurobiol 28:343350.
  • Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95:96089613.
  • Chong RY, Oswald L, Yang X, Uhart M, Lin PI, Wand GS (2006) The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 31:204211.
  • Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L, Minna J (2004) The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 6:229239.
  • Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M, Berlin J, DeMichele A, Bunin G, Strom BL, Rebbeck TR (2005) Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics 15:393398.
  • Coller JK, Joergensen C, Foster DJ, James H, Gillis D, Christrup L, Somogyi AA (2007) Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. Int J Clin Pharmacol Ther 45:410417.
  • Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, Bergen AW, Swan GE, Tyndale RF, Benowitz NL, Lerman C (2008) Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 17:28342848.
  • Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap CB (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80:668681.
  • Dahl JP, Jepson C, Levenson R, Wileyto EP, Patterson F, Berrettini WH, Lerman C (2006) Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J 6:194199.
  • David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR, Shields PG, Lerman C, Strong D, McCaffery J, Niaura R (2007a) Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 9:821833.
  • David SP, Munafo MR, Murphy MF, Proctor M, Walton RT, Johnstone EC (2008) Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J 8:122128.
  • David SP, Munafo MR, Murphy MF, Walton RT, Johnstone EC (2007b) The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob Res 9:225231.
  • David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, Day A, Stumpff J, Hutchison K, Murphy M, Johnstone E, Griffiths SE, Walton RT (2003) Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res 5:935942.
  • David SP, Strong DR, Munafo MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, Evins EA, Shields PG, Lerman C, Niaura R (2007c) Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 9:12511257.
  • de Leon J (2009) Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 34:159172.
  • Deinum J, Steenbergen-Spanjers GC, Jansen M, Boomsma F, Lenders JW, van Ittersum FJ, Huck N, van den Heuvel LP, Wevers RA (2004) DBH gene variants that cause low plasma dopamine beta hydroxylase with or without a severe orthostatic syndrome. J Med Genet 41:e38.
  • Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, Benowitz NL (2004) Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76:6472.
  • Department of Health (2003) Our Inheritance, Our Future: Realising the Potential of Genetics in the NHS. Norwich, UK: The Stationery Office.
  • Department of Health and Human Services (2009) The Genetic Information Nondiscriminisation Act of 2008: Information for Researchers and Health Professionals. Washington DC: Department of Health and Human Services.
  • Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra Grilo L, Deglon JJ, Besson J, Croquette-Krokar M, Carrupt PA, Abriel H (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81:719728.
  • Etter JF, Stapleton JA (2006) Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 15:280285.
  • Fellows JL, Trosclair A, Adams EK, Rivera CC (2002) Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995–1999. Morbidity and Mortality Weekly Report 51(14):300303.
  • Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:8892.
  • Gartner CE, Barendregt JJ, Hall WD (2009) Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction 104:118126.
  • Gaval-Cruz M, Weinshenker D (2009) mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv 9:175187.
  • Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA cooperative study. Alcohol Clin Exp Res 31:555563.
  • Gotti C, Fornasari D, Clementi F (1997) Human neuronal nicotinic receptors. Prog Neurobiol 53:199237.
  • Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA (2004) Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 61:11071115.
  • Gurwitz D, Rehavi M (2005) Pharmacogenetics: towards personalized medicine. Harefuah 144:711716, 750.
  • Gurwitz D, Weizman A, Rehavi M (2003) Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol Sci 24:122125.
  • Heinz A, Reimold M, Wrase J, Hermann D, Croissant B, Mundle G, Dohmen BM, Braus DF, Schumann G, Machulla HJ, Bares R, Mann K (2005) Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62:5764.
  • Heinz A, Schafer M, Higley JD, Krystal JH, Goldman D (2003) Neurobiological correlates of the disposition and maintenance of alcoholism. Pharmacopsychiatry 36 (Suppl 3):S255S258.
  • Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR (2003) Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 118B:6065.
  • Higuchi S, Matsushita S, Masaki T, Yokoyama A, Kimura M, Suzuki G, Mochizuki H (2004) Influence of genetic variations of ethanol-metabolizing enzymes on phenotypes of alcohol-related disorders. Ann N Y Acad Sci 1025:472480.
  • Hu J, Redden DT, Berrettini WH, Shields PG, Restine SL, Pinto A, Lerman C, Allison DB (2006) No evidence for a major role of polymorphisms during bupropion treatment. Obesity 14:18631867.
  • Hughes JR, Stead LF, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev 1:CD000031.
  • Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz NL, Stitzel J, Bryan A, McGeary J, Haughey HM (2007) CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch Gen Psychiatry 64:10781086.
  • Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, Murphy M, Walton R (2006) Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther 80:319330.
  • Johnstone EC, Elliot KM, David SP, Murphy MF, Walton RT, Munafo MR (2007) Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 16:10651069.
  • Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT (2004) Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14:8390.
  • Jones S, Sudweeks S, Yakel JL (1999) Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 22:555561.
  • Kessler DA, Natanblut SL, Wilkenfeld JP, Lorraine CC, Mayl SL, Bernstein IB, Thompson L (1997) Nicotine addiction: a pediatric disease. J Pediatr 130:518524.
  • Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, Kim JG, Choi YS, Kim HO, Kim SY, Oslin DW (2009) A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology 201:611618.
  • Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, Brockmoller J (2003) Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619626.
  • Kohnke MD, Zabetian CP, Anderson GM, Kolb W, Gaertner I, Buchkremer G, Vonthein R, Schick S, Lutz U, Kohnke AM, Cubells JF (2002) A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. Biol Psychiatry 52:11511158.
  • Koob GF, Sanna PP, Bloom FE (1998) Neuroscience of addiction. Neuron 21:467476.
  • Lawford BR, Young RM, Noble EP, Sargent J, Rowell J, Shadforth S, Zhang X, Ritchie T (2000) The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 96:592598.
  • Lawford BR, Young RM, Rowell JA, Qualichefski J, Fletcher BH, Syndulko K, Ritchie T, Noble EP (1995) Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1:337341.
  • Le Foll B, George TP (2007) Treatment of tobacco dependence: integrating recent progress into practice. CMAJ 177:13731380.
  • Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF (2007a) CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 62:635641.
  • Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF (2007b) CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 16:13121314.
  • Lerman C, Berrettini W, Pinto A, Patterson F, Crystal-Mansour S, Wileyto EP, Restine SL, Leonard DG, Shields PG, Epstein LH (2004a) Changes in food reward following smoking cessation:a pharmacogenetic investigation. Psychopharmacology 174:571577.
  • Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W (2006a) Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31:231242.
  • Lerman CE, Schnoll RA, Munafo MR (2007) Genetics and smoking cessation improving outcomes in smokers at risk. Am J Prev Med 33:S398S405.
  • Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 22:541548.
  • Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L (2002) Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12:627634.
  • Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N (2006b) Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 79:600608.
  • Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH (2004b) The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J 4:184192.
  • Lotsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmoller J, Geisslinger G (2006) Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 79:7289.
  • Lucht MJ, Kuehn KU, Schroeder W, Armbruster J, Abraham G, Schattenberg A, Gaensicke M, Barnow S, Tretzel H, Herrmann FH, Freyberger HJ (2001) Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal. Pharmacogenetics 11:647653.
  • MacDonald AW, Schulz SC (2009) What we know: findings that every theory of schizophrenia should explain. Schizophr Bull 35:493508.
  • Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11:400409.
  • Malhotra AK, Murphy GM Jr, Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161:780796.
  • Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP, Evrard A, Cazala P, Cormier A, Mameli-Engvall M, Dufour N, Cloez-Tayarani I, Bemelmans AP, Mallet J, Gardier AM, David V, Faure P, Granon S, Changeux JP (2005) Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436:103107.
  • McCoy CB, Lai S, Metsch LR, Messiah SE, Zhao W (2004) Injection drug use and crack cocaine smoking: independent and dual risk behaviors for HIV infection. Ann Epidemiol 14:535542.
  • McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr (2006) Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 30:12881296.
  • McGehee DS, Role LW (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 57:521546.
  • Messina ES, Tyndale RF, Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:16081614.
  • Mokdad AH, Marks JS, Stroup DF, Gerberding JL (2004) Actual causes of death in the United States, 2000. JAMA 291:12381245.
  • Munafo MR (2009) The clinical utility of genetic tests. Addiction 104:127128.
  • Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC (2007) Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J 7:353361.
  • Munafo MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C (2006a) Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 15:398400.
  • Munafo MR, Murphy MF, Johnstone EC (2006b) Smoking cessation, weight gain, and DRD4-521 genotype. Am J Med Genet B Neuropsychiatr Genet 141B:398402.
  • Munafo MR, Shields AE, Berrettini WH, Patterson F, Lerman C (2005) Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics 6:211223.
  • Musacchio JM, Goldstein M, Anagnoste B, Poch G, Kopin IJ (1966) Inhibition of dopamine-beta-hydroxylase by disulfiram in vivo. J Pharmacol Exp Ther 152:5661.
  • Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:12121217.
  • O'Gara C, Stapleton J, Sutherland G, Guindalini C, Neale B, Breen G, Ball D (2007) Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet Genomics 17:6167.
  • Office of National Drug Control (2004) The Economic Costs of Drug Abuse in the United States, 1992–2002. Washington, DC: Executive Office of the President.
  • Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, van den Brink W (2009) Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol 14:328337.
  • Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:15461552.
  • Oslin DW, Berrettini WH, O'Brien CP (2006) Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict Biol 11:397403.
  • Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, Hawk LW, Tyndale RF, Benowitz N, Lerman C (2008) Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 84:320325.
  • Perez de los Cobos J, Sinol N, Trujols J, del Rio E, Banuls E, Luquero E, Menoyo A, Queralto JM, Baiget M, Alvarez E (2007) Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 89:190194.
  • Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL (2009) Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol Biomarkers Prev 18:26082612.
  • Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173177.
  • Prabat J, Chaloupka FJ (2000) Tobacco Control in Developing Countries. Oxford: Oxford University Press.
  • Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M (2010) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry[Epub ahead of print].
  • Ray LA, Hutchison KE (2007) Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 64:10691077.
  • Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, Pinto A, Berrettini W, Lerman C (2007) Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine Tob Res 9:12371241.
  • Ray LA, Oslin DW (2009) Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. Drug Alcohol Depend 105:256258.
  • Role LW, Berg DK (1996) Nicotinic receptors in the development and modulation of CNS synapses. Neuron 16:10771085.
  • Schank JR, Liles LC, Weinshenker D (2008) Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol Psychiatry 63:10071012.
  • Schank JR, Ventura R, Puglisi-Allegra S, Alcaro A, Cole CD, Liles LC, Seeman P, Weinshenker D (2006) Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 31:22212230.
  • Schnoll RA, Lerman C (2006) Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 11:429444.
  • Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C (2009) Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 92:611.
  • Shields AE, Blumenthal D, Weiss KB, Comstock CB, Currivan D, Lerman C (2005a) Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. J Gen Intern Med 20:131138.
  • Shields AE, Fortun M, Hammonds EM, King PA, Lerman C, Rapp R, Sullivan PF (2005b) The use of race variables in genetic studies of complex traits and the goal of reducing health disparities: a transdisciplinary perspective. Am Psychol 60:77103.
  • Shields A, Lerman C, Sullivan P (2004) Translating emerging research on the genetics of smoking into clinical practice: ethical and social considerations. Nicotine Tob Res 6:675688.
  • Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321327.
  • Substance Abuse and Mental Health Services Administration (2006) Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits, DAWN Series D-30, DHHS Publication No. (SMA) 08-4339, Rockville, MD: Office of Applied Studies. 2008. Available from http://dawninfo.samhsa.gov/files/ED2006/DAWN2k6ED.pdf (accessed 19 January 2011).
  • Swan GE, Jack LM, Valdes AM, Ring HZ, Ton CC, Curry SJ, McAfee T (2007) Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol 26:361368.
  • Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, Curry SJ, McAfee T (2005) Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 5:2129.
  • Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA (2004) Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306:10291032.
  • Thome SL, Malarcher A, Maurice E, Caraballo R (2009) Cigarette smoking among adults––United States, 2007. JAMA 301:373375.
  • Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, David SP, Niaura R, Lerman C (2008) Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 65:683693.
  • Verebey K, Mule SJ (1975) Naltrexone pharmacology, pharmacokinetics, and metabolism: current status. Am J Drug Alcohol Abuse 2:357363.
  • Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A (2002) The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26:106114.
  • Welton NJ, Johnstone EC, David SP, Munafo MR (2008) A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res 10:231240.
  • World Health Organization (2002) The World Health Report: Reducing Risk, Promoting Healthy Life. Geneva: WHO.
  • Wu P, Wilson K, Dimoulas P, Mills EJ (2006) Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 6:300.
  • Xian H, Scherrer JF, Madden PA, Lyons MJ, Tsuang M, True WR, Eisen SA (2003) The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob Res 5:245254.
  • Yardley JP, Husbands GE, Stack G, Butch J, Bicksler J, Moyer JA, Muth EA, Andree T, Fletcher H 3rd, James MN, Sielecki AR (1990) 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: synthesis and antidepressant activity. J Med Chem 33:28992905.
  • Yin SJ, Agarwal DP (2001) Functional polymorphism of ADH and ALDH. In: AgarwalDP, SeitzHK, eds. Alcohol in Health and Disease, pp. 126. New York: Marcel Dekker.
  • Yudkin P, Munafo M, Hey K, Roberts S, Welch S, Johnstone E, Murphy M, Griffiths S, Walton R (2004) Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328:989990.
  • Zabetian CP, Anderson GM, Buxbaum SG, Elston RC, Ichinose H, Nagatsu T, Kim KS, Kim CH, Malison RT, Gelernter J, Cubells JF (2001) A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 68:515522.